Study evaluates CT markers in 474 patients
Brainomix has reported findings from an analysis of 474 patients in Boehringer Ingelheim’s Phase III INBUILD® high-resolution computed tomography (HRCT) sub-study. The study evaluated quantitative CT (qCT) measurements in patients with progressive pulmonary fibrosis (PPF), examining their association with disease progression and sensitivity to antifibrotic treatment.
Researchers assessed quantitative CT measurements using Brainomix e-Lung software and research algorithms developed by the University of California, Los Angeles (UCLA). According to Brainomix, the analysis represents the largest prospective evaluation of quantitative CT in patients with PPF to date.
The study is the first systematic assessment of two quantitative CT approaches using the same dataset. Researchers compared the UCLA quantitative lung fibrosis (QLF) and quantitative interstitial lung disease (QILD) research algorithms with Brainomix e-Lung. The researchers reported broad consistency between the methods.
Quantitative CT measurements and treatment response
The analysis examined changes in quantitative CT measurements in patients receiving nintedanib. Researchers found significant treatment effects on changes in the e-Lung Total Disease Extent (TDE). Significant effects were also observed for the e-Lung Reticulovascular Score (RVS) and Weighted Reticulovascular Score (WRVS) at week 24.
Higher baseline quantitative CT measurements, including TDE, RVS and WRVS, were also associated with a greater rate of forced vital capacity (FVC) decline over 52 weeks.
These findings suggest that quantitative CT measurements may provide information about structural changes in the lungs that complements conventional clinical measures such as FVC. The researchers examined the relationship between imaging measurements, subsequent disease progression and treatment effects.
Potential applications in clinical trials
Commenting on the findings, Professor Anand Devaraj, the study’s lead author and medical director at Brainomix, said: "These findings add to the growing evidence that quantitative CT can provide important information about structural lung disease that may be complementary to conventional measures such as FVC. In this analysis of patients with PPF, quantitative CT measurements were associated with subsequent disease progression and were sensitive to the effects of antifibrotic treatment. The findings support the continued development and incorporation of quantitative CT as an objective biomarker for clinical trials and, potentially, for monitoring disease progression in clinical practice."
The findings add to research into quantitative CT as a complementary measure in PPF clinical trials, with potential applications in evaluating treatment response, assessing disease progression and informing the design of future studies.
Source: Brainomix
